Skip to content

NCEL

NewCelX Ltd.

NASDAQ · Healthcare · Biotechnology · CH

$2.63
+5.20%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-0.8%
EBIT
-68.8%
EPS
+100.9%
Free cash flow
+40.3%
Operating cash flow
+40.3%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
+38.4%
EBIT
+43.5%
Net income
—
EPS
+91.8%
Free cash flow
+35.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026